Ambys Completes $47 Million Series A Extension to Advance Liver Cell Therapy Platform

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Ambys Medicines, a company pioneering cell-based therapies for severe liver diseases, today announced it has completed a $47 million extension of its Series A financing. This brings the total Series A funding raised by Ambys to $107 million. Ambys is developing an entirely new approach to...

Click to view original post